Pfizer update

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs.

Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015.

By the end of this year Pfizer expects to have five different immuno-oncology agents in the clinic that may possibly double by end of 2016.

This entry was posted in crizotinib - Xalkori from Pfizer, Imunotherapies, lorlatinib - Lorbrena by Pfizer. Bookmark the permalink.

Leave a Reply